NCT06627088View on ClinicalTrials.gov

A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Healthy

Interventions

DRUG

LY4100511 (DC-853)

Administered oral dose

DRUG

[14C]-LY4100511 (DC-853) Administered oral dose

Administered oral dose

DRUG

LY4100511 (DC-853)

Administered oral dose

DRUG

[14C]-LY4100511 (DC-853)

Administered IV infusion

Trial Locations (1)

53704

Fortrea Clinical Research Unit, Madison

All Listed Sponsors

lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY

NCT06627088 - A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants | Biotech Hunter | Biotech Hunter